R&D History

2020

2022  Bukwang Pharmaceutical submitted new drug application (NDA) of Lurasidone which is treatment for schizophrenia and bipolar depression

2022  Contera Pharma A/S, a subsidiary of Bukwang Pharm, develops new technology platform called ‘NOVA’ for people suffering from neurological disorders

2022  Contera Pharma A/S, a subsidiary of Bukwang Pharm, signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal

          symptoms and morning akinesia in Parkinson´s disease

2022  Dyna therapeutics, a subsidiary of Bukwang Pharm, announces patent registration of SOL-804 in 32 countries

2022  Bukwang Pharmaceutical succeeds in phase 3 clinical trial for schizophrenia treatment, ‘Lurasidone’

2022  Dyna therapeutics, a subsidiary of Bukwang Pharm, announces completion of phase 1 of SOL-804 for Treatment of prostate cancer by KFDA

 

2021  Dyna therapeutics, a subsidiary of Bukwang Pharm, announces to register U.S. patent for "SOL-804," a candidate substance for anticancer drugs

2021  Dyna therapeutics, a subsidiary of Bukwang Pharm, Announces IND Approval of SOL-804 for treatment of prostate cancer by KFDA

2021  Contera Pharma A/S, a subsidiary of Bukwang Pharm, and abzu partner to design RNA therapeutics for rare diseases using xAI technology

2021  Contera Pharma A/S, a subsidiary of Bukwang Pharm, receives authorization from FDA to Initiate its phase 2 study of JM-010

2021  Dyna therapeutics, a subsidiary of Bukwang Pharm,’s anticancer drug candidate "SOL-804", patent registration completed in Europe, Australia, and Mexico

 

2020  Dyna therapeutics, a subsidiary of Bukwang Pharm,'s anticancer drug candidate "SOL-804", patent registration completed in Japan

2020  Bukwang Pharmaceutical exported the sedative, ‘Midazolam’ to Europe for the treatment of COVID-19

2020  Contera Pharma A/S, a subsidiary of Bukwang Pharm, receives US FDA approval for JM-010 phase 2 clinical study IND

2020  Contera Pharma A/S, a subsidiary of Bukwang Pharm, initiates dosing of JM-010 in Europe phase 2 study

2010

 

2019  University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease

2019  Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries

2018  Bukwang Announces completion of dosing of MLR-1023’s phase 2b study.

2018  Bukwang initiates phase 3 study with lurasidone HCl for patients with Schizophrenia

2018  Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-induced dyskinesia in Parkinson’s disease. - International 

          application and registration of patents on therapeutic use and composition, formulations and metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.

2017  MLR-1023, a novel type 2 diabetic drug candidate, global Phase 2b subject enrollment has initiated

2017  JM-010, a treatment of dyskinesia in PD patients, received orphan drug designation from Korea MFDS

2017  Signed an Korea exclusive license agreement of lurasidone HCl, new drug for schizophrenia, with Sumitomo Dainippon Pharma

2016  Bukwang has entered a distribution deal with Kalbe International Pte. Ltd. to export "Dexid Tab" to six countires, including Philippines and Vietnam.

2016  Anticancer agent Apatinib Mesylate designated orphan drug from Korea MFDS

2015  Phase 2a study of anti-diabetic agent MLR-1023 and Phase 2 study of LID (levodopa-induced dyskinesia) candidate JM-010 each completed

2014  Acquired 100% shares of Danish biotech Contera Pharma

2014  Signed license agreement on JM-010, a candidate for movement disorder in Parkinson’s disease

2013  Acquired approval in Korea for Dexid Tab 480mg (R-thioctic acid tromethamine salt), R-form thioctic acid developed independently by Bukwang

2013  Signed license agreement on MLR-1023, an anti-diabetic candidate

2000

2009  Signed license agreement on YN968D1 (apatinib mesylate), an anti-cancer candidate and VEGFR inhibitor

2009  Acquired approval in Korea for Lonasen Tab. 2mg and 4mg, new drugs for schizophrenia developed by Sumitomo Dainippon Pharma in Japan

2007  Acquired approval in Korea for Nadixa Cream (nadifloxacin), new anti-acne drug developed by Ferrer in Spain

2006  Acquired approval in Korea for Levovir Cap. 30mg (clevudine), the 11th new drug in Korea and a new drug developed by Bukwang

2004  Acquired approval in Korea for Somazina Tab. 500mg (citicoline), a new drug for stroke developed by Ferrer in Spain

2002  Acquired approval in Korea for Thioctacid HR Tab. 600mg and 200mg, new drug for diabetic neuropathy, developed by Meda in Sweden

2001  Acquired approval in Korea for Asima Tab. (doxofylline), a new drug for COPD and asthma, developed by Eurodrug in Ireland

2000  Acquired approval in Korea for Ixel Cap. 50mg and 25mg (milnacipran HCl), a new anti-depressant developed by Pierre Fabre in France

1990

1998  Acquired approval in Korea for Thioctacid Tab. 200mg (thioctic acid), a new drug for diabetic neuropathy

1998  Acquired approval in Korea for Legalon Cap. 140 (Carduus marianus extract powder), a new drug for liver diseases 

1995  Acquired approval in Korea for Navelbine Inj. (vinorelbine tartrate), a new anti-cancer drug for non-small cell lung cancer and progressive breast cancer

1990  Acquired approval in Korea for Bukwang Azeptin Tab. (azelastine HCl), a new drug for allergic rhinitis

1990  Acquired approval in Korea for Orfiril SR Tab. 300mg (sodium valproate), a new drug for epilepsy and mania

1980

 

1986  Acquired approval in Korea for Bukwang Kerlone Tab. (betaxolol HCl), a new beta-blocker for high blood pressure developed by Sanofi-Aventis in France

 

1970

1978  Acquired approval in Korea for Primalan Tab. (mequitazine), a new drug for rash and allergic rhinitis

1974  Acquired approval in Korea for Synthyroid Tab. 0.1mg (levothyroxine sodium hydrate), a new drug for hypothyroidism

 

 

|    ​Korean    |